Here are the DEF 14A proxy statements from ADMA Biologics, Inc. (ADMA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ADMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADMA filings page.
ADMA Biologics, Inc. is calling a virtual 2026 annual stockholder meeting on June 2, 2026 at 10:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/ADMA2026. Stockholders of record at the close of business on April 8, 2026, when 232,324,283 common shares were outstanding, may vote.
Investors will vote on electing two Class I directors, ratifying KPMG LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. The board, which currently has seven members in three staggered classes, recommends voting FOR all proposals.
The proxy describes ADMA’s governance structure, including fully independent Audit, Compensation, and Governance and Nominations Committees, and highlights a pay-for-performance philosophy that combines base salary, annual incentives, and multi-year equity awards. It also discloses major stockholders and equity plan capacity.